CAJ | 학술논문

目的探讨吉西他滨联合顺铂(GP)方案和紫杉醇联合顺铂(TP)方案对初治的晚期非小细胞肺癌(NSCLC)的疗效和不良反应.方法 66例初治晚期NSCLC患者随机分为GP组(34例)和TP组(32例).GP组:吉西他滨1000 ms/m2,第1、8天;顺铂30 ms/m2,第1～3天.TP组:紫杉醇135 mg/m2,第1天;顺铂30 ms/m2,第1～3天.化疗2个周期后对两组的临床疗效和不良反应进行评价.结果 GP和TP两组的有效率分别为41.2%(14/34)和40.6%(13/32).两组资料比较差异无统计学意义.GP组以血小板降低为主,TP组以白细胞降低为主,均在可耐受范围内.结论 GP方案和TP方案对晚期NSCLC疗效肯定,不良反应有一定差异,可根据不同个体选用不同的化疗方案.
목적 탐토길서타빈연합순박(GP)방안화자삼순연합순박(TP)방안대초치적만기비소세포폐암(NSCLC)적료효화불량반응.방법 66례초치만기NSCLC환자수궤분위GP조(34례)화TP조(32례).GP조:길서타빈1000 ms/m2,제1、8천;순박30 ms/m2,제1～3천.TP조:자삼순135 mg/m2,제1천;순박30 ms/m2,제1～3천.화료2개주기후대량조적림상료효화불량반응진행평개.결과 GP화TP량조적유효솔분별위41.2%(14/34)화40.6%(13/32).량조자료비교차이무통계학의의.GP조이혈소판강저위주,TP조이백세포강저위주,균재가내수범위내.결론 GP방안화TP방안대만기NSCLC료효긍정,불량반응유일정차이,가근거불동개체선용불동적화료방안.
Objective To investigate the efficacy and toxicity of the GP regimen and TP regimen on advanced non-small cell lung cancer(NSCLC).Methods Sixty-six advanced NSCLC patients were randomly divided into two groups.34 in GP group and 32 in TP group.GP group:gemeitabine 1000 ms/m2,d1、d8;cisplatin 30 ms/m2,d1～3.TP group:paclitaxel 135 ms/m2,d1;cisplatin 30 ms/m2,d1～3.The efficacy and side effects were analyzed after two cycles of chemotherapy.Results The short term effective rate for Mvanced NSCLC in GP group andTP group was41.2%(14/34)and 40.6%(13/32),110 significant statistical difference was found between the two groups(P>0.05).In the adverse effects of treatment,the major cytotoxicity was thrombocytopenia in GP group and leukopenia in TP group but they were tolerable.Conclusion The curative effect of GP regimen and TP regimen are affirmed.there are certain differences in adverse reactions.Different themes can be chosen according to different choices in patients with Mvanced non=small cell lung cancer.